source
- Roche cans one Carmot obesity asset as another shows best-in-class potentialAcmopatide met the main goal of a Phase 2 study in type 1 diabetes, but Roche is axing the investigational drug to prioritize enicepatide for weight loss, type 2 diabetes and cardiovascular outcome…BioSpace · 4d ago↗ source
- Update: FDA does not freeze CRL trove as ‘radical transparency’ push hits speedbumpAn unnamed pharma filed a citizen petition in April seeking reforms to the way the FDA publicly releases rejection letters, alleging that the policy “contravenes decades of agency practice.”BioSpace · 5d ago↗ source
- BeOne commits $300M to US manufacturing expansion, creating 120 new jobsThe addition of small molecule capacity at BeOne Medicines’ Hopewell site will support the company’s hematology efforts and bring total investment in the campus to more than $1 billion.